About Protara therapeutics

About company

tenacious in our search for transformative therapies LEARN ABOUT US TARA-002 TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for multiple oncologic indications and lymphatic malformations (LMs). We are ...